The 8,600m2 facility provides “filtration, separation and purification support and training capabilities for a growing base of life sciences customers,” said Pall Corporation spokesman Doug Novarro.
Though Pall has been in the Chinese market for over twenty years, he told Biopharma-Reporter.com: “The opening of our China Life Sciences CoE reinforces our continued commitment to this region.”
He continued, telling us, the site would showcase Pall’s full range of life science equipment and disposable solutions. These include:
“MicroReactors, Bioreactors, single-use systems , depth filter systems, Stax systems, tangential flow filtration (TFF) systems, chromatography systems, process monitoring, sterile filters and others.”
Though there are differences in China regarding regulations and requirements, Pall employs “local talent in China to better understand and address local needs,” Novarro said.
“With our local team of highly qualified engineers and scientists, we will be able to cater specifically to the process development needs of the expanding base of drug manufacturers in China.”
Further benefits for Pall’s China-based customers include the ability to use the facility as a springboard to explore international markets, he added, on top of a shorter cycle time for reports due to its expanded validation services capability.
Whilst local biomanufacturing firms such as Wuxi have been leading the way for biologics in China, there have been several large Western companies looking at this region of late.
Boehringer Ingelheim commenced a joint venture with a Shanghai company in June, whilst GE Healthcare recently penned a deal with JHL Biotech to build a modular biopharma plant in Wuhan.